The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Delta opioid receptors in brain function and diseases
Open accessAbstract
Evidence that the delta opioid receptor (DOR) is an attractive target for the treatment of brain disorders has strengthened in recent years. This receptor is broadly expressed in the brain, binds endogenous opioid peptides, and shows as functional profile highly distinct from those of mu and kappa opioid receptors. Our knowledge of DOR function has enormously progressed from in vivo studies using pharmacological tools and genetic approaches. The important role of this receptor in reducing chronic pain has been extensively overviewed; therefore this review focuses on facets of delta receptor activity relevant to psychiatric and other neurological disorders. Beneficial effects of DOR agonists are now well established in the context of emotional responses and mood disorders. DOR activation also regulates drug reward, inhibitory controls and learning processes, but whether delta compounds may represent useful drugs in the treatment of drug abuse remains open. Epileptogenic and locomotor-stimulating effects of delta agonists appear drug-dependent, and the possibility of biased agonism at DOR for these effects is worthwhile further investigations to increase benefit/risk ratio of delta therapies. Neuroprotective effects of DOR activity represent a forthcoming research area. Future developments in DOR research will benefit from in-depth investigations of DOR function at cellular and circuit levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
LeDoux, J. E. (2000) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.23.1.155 · Cited by 8,444
Emotional processing in anterior cingulate and medial prefrontal cortex
Etkin, A., Egner, T., & Kalisch, R. (2011) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2010.11.004 · Cited by 3,059 · cited 1×
“DORs are expressed in sensory regions (green circles), brain areas important for the regulation of anxiety and depression (blue circles adapted from (File et al., 2000; LeDoux, 2000; Cardinal et al., 2002; B. J. Everitt et al., 2003; Paulus & Stein, 2006; Rodrigues et al., 2009; Etkin et al., 2011; Gross & Canteras, 2…”
BackgroundGoal-directed instrumental action: contingency and incentive learning and their cortical substrates
Balleine, B. W., & Dickinson, A. (1998) · Neuropharmacology · doi:10.1016/s0028-3908(98)00033-1 · Cited by 1,541
Paulus, M. P., & Stein, M. B. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.042 · Cited by 1,325
Reward Processing by the Opioid System in the Brain
Le Merrer, J., Becker, J. A. J., Befort, K., & Kieffer, B. L. (2009) · Physiological Reviews · doi:10.1152/physrev.00005.2009 · Cited by 1,013
Self-citationMice deficient for δ- and μ-opioid receptors exhibit opposing alterations of emotional responses
Filliol, D., Ghozland, S., Chluba, J., Martin, M., Matthes, H. W. D., Simonin, F., Befort, K., Gavériaux-Ruff, C., Dierich, A., LeMeur, M., et al. (2000) · Nature Genetics · doi:10.1038/76061 · Cited by 672
Self-citationDrug addiction: the neurobiology of disrupted self-control
Baler, R. D., & Volkow, N. D. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.10.005 · Cited by 640 · cited 1×
“…2008), the setting of aberrant learningmechanisms (Belin et al., 2009) and habitual behaviors (Everitt et al., 2008), the disruption of self-control (Baler & Volkow, 2006) and the engagement of cue-induced relapse mechanisms (Pickens et al., 2011), which all contribute to maintaining drug use.”
BackgroundGross, C. T., & Canteras, N. S. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3301 · Cited by 596
Opioid receptors: Distinct roles in mood disorders
Lutz, P.-E., & Kieffer, B. L. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2012.11.002 · Cited by 542
Self-citationBelin, D., Jonkman, S., Dickinson, A., Robbins, T. W., & Everitt, B. J. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.09.027 · Cited by 520
Cited by
Molecular Targets of Cannabidiol in Neurological Disorders
Ibeas Bih, C., Chen, T., Nunn, A. V. W., Bazelot, M., Dallas, M., & Whalley, B. J. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0377-3 · Cited by 578
Opioid receptors: drivers to addiction?
Darcq, E., & Kieffer, B. L. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0028-x · Cited by 352
Self-citationA narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD)
Peng, J., Fan, M., An, C., Ni, F., Huang, W., & Luo, J. (2022) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13710 · Cited by 282
Opioid system and human emotions
Nummenmaa, L., & Tuominen, L. (2018) · British Journal of Pharmacology · doi:10.1111/bph.13812 · Cited by 178
Opioid Receptor-Mediated Regulation of Neurotransmission in the Brain
Reeves, K. C., Shah, N., Muñoz, B., & Atwood, B. K. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.919773 · Cited by 156
The opioid system and the social brain: implications for depression and suicide
Lutz, P., Courtet, P., & Calati, R. (2020) · Journal of Neuroscience Research · doi:10.1002/jnr.24269 · Cited by 53
Chiappini, S., Schifano, F., Corkery, J. M., & Guirguis, A. (2020) · Brain Sciences · doi:10.3390/brainsci10020105 · Cited by 33
Focusing on the Opioid System for Addiction Biomarker Discovery
Belzeaux, R., Lalanne, L., Kieffer, B. L., & Lutz, P.-E. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.12.004 · Cited by 28
Metadata
- Authors
- Chu Sin Chung, P., & Kieffer, B. L.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2013-10
- Volume
- 140
- Issue
- 1
- Pages
- 112-120
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2060389245
- Cited by
- 159
- References
- 12
- FWCI
- 7.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.